NEW YORK (GenomeWeb) – French companion diagnostics firm ImmunID announced today that it has signed a deal with Memorial Sloan Kettering Cancer Center (MSKCC) to clinically validate its ImmunTracker assay as a predictor of patient response to cancer immunotherapy.

ImmunTracker is a PCR-based system that detects gene recombinations in T cells, providing data about how a cancer patient's immune system is responding to a particular immunotherapy. In collaboration with MSKCC, ImmunID aims to test the assay in solid tumor patients being treated with immune checkpoint inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.